Skip to main content
Top
Published in: Seminars in Immunopathology 1/2011

01-01-2011 | Review

Beta cell regeneration in human pancreas

Author: Roberto Gianani

Published in: Seminars in Immunopathology | Issue 1/2011

Login to get access

Abstract

The issue of beta cell regeneration in human pancreas is probably one of the most controversial aspects of type 1 diabetes research. In this review, we will first describe the known mechanisms underlying beta cell development and expansion in normal human pancreatic development because it is likely that such mechanisms might also play a role in beta cell regeneration. The sensu strictiori definition of beta cells implies replacement of lost beta cell mass by new beta cells. In our discussion, however, we will use the term in a more general way, defining as regeneration the formation of new beta cells, whether or not a loss of beta cells has actually occurred. The potential mechanisms of beta cell regeneration in the human pancreas will be discussed in the second part of this review. In particular, we will analyze beta cell regeneration through proliferation of beta cells, neogenesis from non-beta cell precursors, and transdifferentiation from alpha cells. In the third part of this review, we will explore the arguments for and against the ability of the human pancreas to regenerate functional beta cells in the context of type 1 diabetes and in other pathological conditions.
Literature
1.
go back to reference (2010) Beta-cell development and turnover during prenatal life in humans. Eur J Endocrinol 162: 559–568 (2010) Beta-cell development and turnover during prenatal life in humans. Eur J Endocrinol 162: 559–568
2.
go back to reference (2004) Nesidioblastosis: an old term and a new understanding. World J Surg 28(12):1227–30 (2004) Nesidioblastosis: an old term and a new understanding. World J Surg 28(12):1227–30
3.
go back to reference (2006) Beta-cell proliferation is the major source of new pancreatic beta cells. Nat Clin Pract Endocrinol Metabol 2(5):242–3 (2006) Beta-cell proliferation is the major source of new pancreatic beta cells. Nat Clin Pract Endocrinol Metabol 2(5):242–3
4.
go back to reference (2010) Glucose and aging control the quiescence period that follows pancreatic beta cell replication. Development 137(19):3205–13 (2010) Glucose and aging control the quiescence period that follows pancreatic beta cell replication. Development 137(19):3205–13
5.
go back to reference Expansion of beta cell mass in response to pregnancy. Trends in endocrinology and metabolism. Vol 21 Number 3 Expansion of beta cell mass in response to pregnancy. Trends in endocrinology and metabolism. Vol 21 Number 3
6.
go back to reference (2010) Beta-cell growth and regeneration: replication is only part of the story. Diabetes 59(10):2340–8 (2010) Beta-cell growth and regeneration: replication is only part of the story. Diabetes 59(10):2340–8
7.
go back to reference Initial results of screening of non-diabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metabol 91(5):1855–1861 Initial results of screening of non-diabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metabol 91(5):1855–1861
8.
go back to reference (2008) Insulin protein and proliferation in ductal cells in the transplanted pancreas of patients with type 1 diabetes and recurrence of autoimmunity. Diabetologia 51(10):1803–13 (2008) Insulin protein and proliferation in ductal cells in the transplanted pancreas of patients with type 1 diabetes and recurrence of autoimmunity. Diabetologia 51(10):1803–13
9.
go back to reference (2010) Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464(7292):1149–54 (2010) Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464(7292):1149–54
10.
go back to reference (2010) Pancreatic β-cell neogenesis by direct conversion from mature α-cells. Stem cells 28(9):1630–8 (2010) Pancreatic β-cell neogenesis by direct conversion from mature α-cells. Stem cells 28(9):1630–8
11.
go back to reference (2008) Type 1 diabetes: chronic progressive autoimmune disease. Novartis Found Symp 292:85–203 (2008) Type 1 diabetes: chronic progressive autoimmune disease. Novartis Found Symp 292:85–203
12.
go back to reference (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26(8):2345–52 (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26(8):2345–52
13.
go back to reference (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48(11): 2221–8. (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48(11): 2221–8.
14.
go back to reference (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53(4):690–8 (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53(4):690–8
Metadata
Title
Beta cell regeneration in human pancreas
Author
Roberto Gianani
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 1/2011
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-010-0235-7

Other articles of this Issue 1/2011

Seminars in Immunopathology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine